Clinical Biomarkers Impact Factor|OMICS International|Journal Of Molecular Biomarkers And Diagnosis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Clinical Biomarkers Impact Factor

Impact Factor is an indicator of the number of citations within the scientific journals of clinical and medical category. Impact factor is measured based on the frequency with which a journal's articles are cited in scientific publications, is a putative marker of journal quality. Publication ccitation, index of researchers, and journal impact factors are used to measure the impact & importance of research. Journal Impact factor are most widely used metric for measuring the quality of clinical Journal. Clinical Journals impact factor can be improved by using various study methods, includes assigning more referees to check the quality of the submitted articles and thus nominating their journals for indexing in databases. Early detection and differential diagnosis of a disease is a significant challenge. Asymptomatic disease present in an unknown location in the body has to be identified precisely, inexpensively, and quickly. Only a few types of clinical biomarkers can accomplish this task, including epigenetic biomarkers based on Methylation of cell-free circulating DNA in blood.In this presentation an overview of a novel technology for genome-wide detection of DNA methylation in ultra-small samples, MethDet, will be presented alongside with results of the proof-of-principle platform for identification of abnormal DNA methylation patterns in each sample. This platform allows identification of advanced adenoma of the colon, ductal carcinoma in situ, and stage I/II colon cancer. The possibility of differential diagnosis by blood analysis has been established by comparison of patterns between benign lesions of the breast vs. ductal carcinoma, and benign ovarian disease vs. adenocarcinoma of the ovary. Application of DNA methylome-wide analysis to differential diagnosis of cancer, psychiatric, and neurological diseases will be discussed. Drug-specific changes in DNA methylation patterns detected in cell-free circulating DNA from blood of drug-exposed patients will be demonstrated.(Victor V. Levenson and Anotoliy A Melnikov, DNA methylome analysis in blood using the MethDet technology: A universal media for clinical biomarkers)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on May, 2021